Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Group 1: Earnings Performance - Rigel Pharmaceuticals reported quarterly earnings of $3.28 per share, exceeding the Zacks Consensus Estimate of $1.97 per share, compared to a loss of $0.06 per share a year ago, representing an earnings surprise of +66.50% [1] - The company posted revenues of $101.69 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.99%, compared to year-ago revenues of $36.84 million [2] - Rigel has surpassed consensus EPS estimates four times over the last four quarters [2] Group 2: Stock Performance and Outlook - Rigel shares have increased approximately 34.8% since the beginning of the year, outperforming the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.26 on revenues of $50.63 million, and $2.68 on revenues of $236.7 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Drugs industry, to which Rigel belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Rigel's stock performance [5] - Another company in the same industry, Nektar Therapeutics, is expected to report a quarterly loss of $2.65 per share, with revenues projected to be $10.78 million, down 54.1% from the year-ago quarter [9][10]